Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).

In Dermatology
by ClinOwl September 21, 2020

Data for the effect of metabolic syndrome (MetS) on efficacy and safety of biologic agents for psoriasis treatment are limited.To evaluate long-term tildrakizumab efficacy, drug survival, and safety in patients […]

U.S. Burden of Skin and Subcutaneous Diseases Increasing

Can dermatology employers require employees to receive the COVID-19 vaccine?

THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

Expression of retinoid receptors in hand eczema.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).